• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Sabin 灭活脊灰病毒疫苗(sIPV)在冷链中暴露于冷冻温度后的效力。

Potency of the Sabin inactivated poliovirus vaccine (sIPV) after exposure to freezing temperatures in cold chains.

机构信息

Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College , Kunming, Yunnan, China.

Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases , Kunming, Yunnan, China.

出版信息

Hum Vaccin Immunother. 2020 Aug 2;16(8):1866-1874. doi: 10.1080/21645515.2019.1709352. Epub 2020 Mar 2.

DOI:10.1080/21645515.2019.1709352
PMID:32118517
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7482872/
Abstract

With more demand for Sabin inactivated poliovirus vaccines (sIPVs) to support the global polio eradication effort worldwide, data regarding the potency characteristics of sIPV after exposure to freezing temperatures are urgently required. In the present study, the sIPVs were stored at -20°C for 24 h, 1 week, and 2 weeks in the freezer or in a vaccine carrier for 1 or 3 freeze-thaw cycle to evaluate the effect mediated by freezing temperatures that may be encountered during routine storage and transfer. The potency was then determined by a D-antigen enzyme-linked immunosorbent assay, and the potency was evaluated in Wistar rats. In the study for freezer storage groups, the D-antigen contents for all three types decreased and were lower than the release specifications after storing at -20°C for 2 weeks. After storing at -20°C for 1 week, the D-antigen contents for types I and III in combined group of a total of 45 vials, and for type II in the specific lot groups containing 15 vials decreased, but were within the release specifications. Moreover, no significant change in potency was observed. For vaccine carrier transfer groups, the D-antigen contents did not decrease after 1 freeze-thaw cycle; in contrast, it decreased, but no significant potency loss was observed after 3 freeze-thaw cycles. These results suggest that it may be possible to retain sufficient sIPV potency after short periods of freezing or freeze-thawing during transport.

摘要

随着全球消灭脊灰行动对沙宾型灭活脊灰病毒疫苗(sIPV)需求的增加,迫切需要了解 sIPV 在暴露于冷冻温度后的效力特征数据。在本研究中,sIPV 在冰箱中于-20°C 储存 24 小时、1 周和 2 周,或在疫苗冷藏盒中储存 1 次或 3 次冻融循环,以评估在常规储存和运输过程中可能遇到的冷冻温度的影响。然后通过 D 抗原酶联免疫吸附测定法测定效力,并在 Wistar 大鼠中评估效力。在冷冻储存组的研究中,三种类型的 D 抗原含量均降低,且低于释放规格,在-20°C 储存 2 周后。在-20°C 储存 1 周后,共有 45 支小瓶的 I 型和 III 型组合以及含有 15 支小瓶的 II 型的 D 抗原含量降低,但仍在释放规格内。此外,效力没有明显变化。对于疫苗冷藏盒转移组,1 次冻融循环后 D 抗原含量没有下降;相反,在 3 次冻融循环后,D 抗原含量下降,但没有明显的效力损失。这些结果表明,在运输过程中短暂的冷冻或冻融后,sIPV 的效力可能得以保留。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/e8e182a171d6/KHVI_A_1709352_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/72f0b502bc58/KHVI_A_1709352_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/adadec4e8244/KHVI_A_1709352_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/2320ca4a16da/KHVI_A_1709352_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/b1efb333008c/KHVI_A_1709352_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/f8f41bd28e21/KHVI_A_1709352_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/f77a9b176fc9/KHVI_A_1709352_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/e8e182a171d6/KHVI_A_1709352_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/72f0b502bc58/KHVI_A_1709352_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/adadec4e8244/KHVI_A_1709352_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/2320ca4a16da/KHVI_A_1709352_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/b1efb333008c/KHVI_A_1709352_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/f8f41bd28e21/KHVI_A_1709352_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/f77a9b176fc9/KHVI_A_1709352_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c7/7482872/e8e182a171d6/KHVI_A_1709352_F0007_OC.jpg

相似文献

1
Potency of the Sabin inactivated poliovirus vaccine (sIPV) after exposure to freezing temperatures in cold chains.Sabin 灭活脊灰病毒疫苗(sIPV)在冷链中暴露于冷冻温度后的效力。
Hum Vaccin Immunother. 2020 Aug 2;16(8):1866-1874. doi: 10.1080/21645515.2019.1709352. Epub 2020 Mar 2.
2
Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.耐热冻干脊髓灰质炎疫苗的研制。
mBio. 2018 Nov 27;9(6):e02287-18. doi: 10.1128/mBio.02287-18.
3
Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.Sabin 活疫苗衍生和野生型脊灰病毒株制备的灭活脊灰疫苗的抗原结构差异:对疫苗效力检测的影响。
J Infect Dis. 2020 Feb 3;221(4):544-552. doi: 10.1093/infdis/jiz076.
4
Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures.评估暴露于冷冻温度后灭活脊髓灰质炎疫苗的效力和免疫原性。
Biologicals. 2018 May;53:30-38. doi: 10.1016/j.biologicals.2018.03.002. Epub 2018 Mar 14.
5
A national reference for inactivated polio vaccine derived from Sabin strains in Japan.日本源自萨宾株的灭活脊髓灰质炎疫苗的国家参考品。
Vaccine. 2014 Sep 8;32(40):5163-9. doi: 10.1016/j.vaccine.2014.07.065. Epub 2014 Jul 30.
6
Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.中国浙江三种序贯接种程序使用沙宾灭活脊髓灰质炎疫苗和二价口服脊髓灰质炎疫苗的免疫原性:一项开放标签、随机、对照试验
Lancet Infect Dis. 2020 Sep;20(9):1071-1079. doi: 10.1016/S1473-3099(19)30738-8. Epub 2020 May 19.
7
Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV).分析含佐剂的脊髓灰质炎灭活疫苗(sIPV)的剂量节约效应。
Hum Vaccin Immunother. 2018;14(8):1987-1994. doi: 10.1080/21645515.2018.1454571. Epub 2018 May 10.
8
Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats.Sabin 来源的灭活脊灰疫苗热变性对大鼠 D 抗原性和免疫原性的影响。
Vaccine. 2020 Apr 9;38(17):3295-3299. doi: 10.1016/j.vaccine.2020.03.027. Epub 2020 Mar 17.
9
Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.在日本开发和引进源自 Sabin 株的脊髓灰质炎灭活疫苗。
Vaccine. 2016 Apr 7;34(16):1975-85. doi: 10.1016/j.vaccine.2014.11.015. Epub 2014 Nov 21.
10
[Immunogenicity of sabin inactivated poliovirus vaccine induced by diphtheria-tetanus-acellular pertussis and Sabin inactivated poliovirus combined vaccine].白喉-破伤风-无细胞百日咳与脊髓灰质炎灭活疫苗(Sabin株)联合疫苗诱导的脊髓灰质炎灭活疫苗(Sabin株)免疫原性
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011 Jun;25(3):197-200.

引用本文的文献

1
Integrated Analytical Techniques to Investigate the Effect of the Freezing/Thawing Cycles on the Non-replicating Recombinant Chimpanzee Adenovirus Viral Vector COVID-19 Vaccine.综合分析技术研究冻融循环对非复制型重组黑猩猩腺病毒载体COVID-19疫苗的影响
AAPS PharmSciTech. 2025 Sep 10;26(7):226. doi: 10.1208/s12249-025-03220-6.
2
A highly immunogenic UVC inactivated Sabin based polio vaccine.一种具有高度免疫原性的基于萨宾株的紫外线灭活脊髓灰质炎疫苗。
NPJ Vaccines. 2024 Nov 14;9(1):217. doi: 10.1038/s41541-024-00995-w.
3
Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.

本文引用的文献

1
Temperature integrity and exposure to freezing temperature during vaccine transfer under the universal immunization program in Three States of India.印度三个邦的国家免疫计划下疫苗运输过程中的温度完整性和暴露于冷冻温度。
Indian J Public Health. 2019 Apr-Jun;63(2):139-142. doi: 10.4103/ijph.IJPH_123_18.
2
Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.Sabin 活疫苗衍生和野生型脊灰病毒株制备的灭活脊灰疫苗的抗原结构差异:对疫苗效力检测的影响。
J Infect Dis. 2020 Feb 3;221(4):544-552. doi: 10.1093/infdis/jiz076.
3
用于降低成本、提高覆盖率并促进脊髓灰质炎根除的灭活脊髓灰质炎疫苗的当前和下一代配方策略。
Hum Vaccin Immunother. 2022 Dec 30;18(7):2154100. doi: 10.1080/21645515.2022.2154100. Epub 2022 Dec 28.
4
Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.含铝佐剂和 CpG 佐剂的 SARS-CoV-2 受体结合域(RBD)抗原的抗原-佐剂相互作用、稳定性和免疫原性特征。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2079346. doi: 10.1080/21645515.2022.2079346. Epub 2022 Jun 6.
Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures.
评估暴露于冷冻温度后灭活脊髓灰质炎疫苗的效力和免疫原性。
Biologicals. 2018 May;53:30-38. doi: 10.1016/j.biologicals.2018.03.002. Epub 2018 Mar 14.
4
Stability of an aluminum salt-adjuvanted protein D-conjugated pneumococcal vaccine after exposure to subzero temperatures.铝佐剂蛋白 D 缀合肺炎球菌疫苗在暴露于亚零下温度后的稳定性。
Hum Vaccin Immunother. 2018 May 4;14(5):1243-1250. doi: 10.1080/21645515.2017.1421878. Epub 2018 Feb 12.
5
Monitoring Results in Routine Immunization: Development of Routine Immunization Dashboard in Selected African Countries in the Context of the Polio Eradication Endgame Strategic Plan.常规免疫监测结果:在脊髓灰质炎根除终局战略计划背景下选定非洲国家常规免疫仪表盘的开发
J Infect Dis. 2017 Jul 1;216(suppl_1):S226-S236. doi: 10.1093/infdis/jiw635.
6
Is freezing in the vaccine cold chain an ongoing issue? A literature review.疫苗冷链中的冻结是一个持续存在的问题吗?一项文献综述。
Vaccine. 2017 Apr 19;35(17):2127-2133. doi: 10.1016/j.vaccine.2016.09.070.
7
Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014.引入灭活脊髓灰质炎疫苗以推进脊髓灰质炎根除终局战略计划;中国杭州,2010 - 2014年
Vaccine. 2017 Mar 1;35(9):1281-1286. doi: 10.1016/j.vaccine.2017.01.034. Epub 2017 Feb 1.
8
Polio vaccines: WHO position paper – March, 2016.脊髓灰质炎疫苗:世界卫生组织立场文件 - 2016年3月
Wkly Epidemiol Rec. 2016 Mar 25;91(12):145-68.
9
World Health Organization Guidelines for Containment of Poliovirus Following Type-Specific Polio Eradication - Worldwide, 2015.世界卫生组织 2015 年关于特定类型脊灰病毒根除后病毒控制的指南-全球范围
MMWR Morb Mortal Wkly Rep. 2015 Aug 28;64(33):913-7. doi: 10.15585/mmwr.mm6433a5.
10
Factors associated with the exposure of vaccines to adverse temperature conditions: the case of North West region, Cameroon.与疫苗暴露于不利温度条件相关的因素:喀麦隆西北地区的案例
BMC Res Notes. 2015 Jun 30;8:277. doi: 10.1186/s13104-015-1257-y.